Stock Analysis

3 US Penny Stocks With Market Cap Under $70M

As the S&P 500 edges toward new highs amidst mixed trading sessions, investors are paying close attention to smaller market segments for potential opportunities. Penny stocks, though an older term, continue to represent a compelling area of interest due to their association with smaller or emerging companies that might offer significant growth potential. By focusing on those with strong financials and solid fundamentals, investors can find unique opportunities in this often-overlooked segment of the market.

Advertisement

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapFinancial Health Rating
QuantaSing Group (NasdaqGM:QSG)$3.08$110.92M★★★★★★
BAB (OTCPK:BABB)$0.87505$6.41M★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)$3.87$12M★★★★★★
Inter & Co (NasdaqGS:INTR)$4.97$2.09B★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)$0.2896$11.03M★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)$4.50$67.38M★★★★★★
BTCS (NasdaqCM:BTCS)$3.12$59.16M★★★★★★
Smith Micro Software (NasdaqCM:SMSI)$1.28$22.17M★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)$0.9272$82.51M★★★★★☆
Safe Bulkers (NYSE:SB)$3.31$361.98M★★★★☆☆

Click here to see the full list of 710 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Grace Therapeutics (NasdaqCM:GRCE)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grace Therapeutics, Inc. focuses on developing and commercializing pharmaceutical products for rare and orphan diseases in Canada, with a market cap of $37.72 million.

Operations: Grace Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $37.72M

Grace Therapeutics, Inc., with a market cap of US$37.72 million, is a pre-revenue company focusing on rare diseases. Despite being unprofitable, it has reduced losses over the past five years by 4.7% annually and maintains no debt. The management and board are relatively inexperienced with average tenures under two years. Recent presentations at industry events highlight its active engagement in the biotech community despite high share price volatility and negative return on equity (-20.68%). With short-term assets of US$16.1 million exceeding liabilities, Grace has more than a year's cash runway based on current free cash flow trends.

NasdaqCM:GRCE Financial Position Analysis as at Jan 2025
NasdaqCM:GRCE Financial Position Analysis as at Jan 2025

Generation Bio (NasdaqGS:GBIO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Generation Bio Co. develops non-viral genetic medicines for treating rare and prevalent diseases, with a market cap of $66.12 million.

Operations: The company's revenue is derived entirely from its Pharmaceuticals segment, totaling $18.58 million.

Market Cap: $66.12M

Generation Bio Co., with a market cap of US$66.12 million, is pre-revenue and focuses on genetic medicines. Recent executive changes include Kevin Conway as CFO and Phillip Samayoa as CSO, reflecting strategic shifts. The company is advancing its T cell-directed lipid nanoparticle (ctLNP) technology for siRNA therapeutics, addressing autoimmune diseases by modulating T cell function. Financially stable with no debt and short-term assets of US$191.3 million exceeding liabilities, it has a cash runway of over two years despite ongoing losses. A recent shelf registration filing indicates potential capital raising to support development efforts.

NasdaqGS:GBIO Financial Position Analysis as at Jan 2025
NasdaqGS:GBIO Financial Position Analysis as at Jan 2025

Koil Energy Solutions (OTCPK:KLNG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Koil Energy Solutions, Inc. is an energy services company that offers equipment and support services to the energy and offshore industries, with a market cap of $26.26 million.

Operations: The company generates revenue of $20.80 million from its Oil Well Equipment & Services segment.

Market Cap: $26.26M

Koil Energy Solutions, with a market cap of US$26.26 million, has shown significant financial improvement, becoming profitable this year with a net income of US$2.08 million for the first nine months of 2024. The company's revenue from its Oil Well Equipment & Services segment reached US$16.79 million, marking growth from the previous year. It operates debt-free and maintains strong liquidity, as short-term assets exceed both short and long-term liabilities. Despite stable earnings quality and no shareholder dilution recently, Koil's share price remains highly volatile over recent months compared to most U.S. stocks.

OTCPK:KLNG Revenue & Expenses Breakdown as at Jan 2025
OTCPK:KLNG Revenue & Expenses Breakdown as at Jan 2025

Seize The Opportunity

  • Investigate our full lineup of 710 US Penny Stocks right here.
  • Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
  • Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:GBIO

Generation Bio

A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.

Adequate balance sheet with low risk.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
67 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

YI
XRAY logo
yiannisz on DENTSPLY SIRONA ·

Dentsply Sirona Stock: Dental Technology Built for Cycles, Not Headlines

Fair Value:US$45.575.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ETSY logo
yiannisz on Etsy ·

Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces

Fair Value:US$64.4511.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ALGN logo
yiannisz on Align Technology ·

Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World

Fair Value:US$154.620.9% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
67 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1015 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative